Soraprazan (C09-1170-124)

Soraprazan (BYK61359) is a selective, reversible K-competitive inhibitor of the H,K-ATPase ( K i =6.4 nM), with an IC 50 of 0.19 μM in gastric glands. Soraprazan binds to the H,K-ATPase with a Kd of 28.27 nM. Soraprazan shows immediate inhibition of acid secretion and is more than 2000-fold selective for H,K-ATPase over Na,K- and Ca-ATPases.In VitroSoraprazan (BYK61359) is a potent inhibitor of gastric H,K-ATPase, with an IC 50 of 0.1 μM when measured in ion-leaky vesicles in the presence of 1 mM potassium. Soraprazan (BYK61359) also effectively inhibits dibutyryl cAMP-stimulated [ 14 C]AP accumulation in isolated gastric glands with an IC 50 of 0.19 μM (0.09-0.40 μM geometric mean from n=6 with 95% confidence limits). MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoSoraprazan (1-27 μmol/kg; p.o.) shows rapid and consistent inhibition of acid secretion in dog . MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:Solid. Specification: 0.99 Molecular Formula: C21H25N3O3 Molecular Weight: 367.44 PubChem CID: 213054 Isomeric SMILES: CC1=C(N2C=CC3=C(C2=N1)N[C@@H]([C@H]([C@@H]3OCCOC)O)C4=CC=CC=C4)C